An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
Avian influenza: A vaccine for a deadly emergent strain A vaccine candidate to treat a deadly subtype of avian influenza was shown to induce protective antibodies in initial clinical trials. As of March 2017, avian influenza strain A/H7N9 has killed 497 people since 2013, with 1349 confirmed cases....
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-06-01
|
Series: | npj Vaccines |
Online Access: | https://doi.org/10.1038/s41541-017-0016-6 |
id |
doaj-e2d2da024d7c4739ac5a7e10fb271246 |
---|---|
record_format |
Article |
spelling |
doaj-e2d2da024d7c4739ac5a7e10fb2712462020-12-07T23:56:32ZengNature Publishing Groupnpj Vaccines2059-01052017-06-01211610.1038/s41541-017-0016-6An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trialAdam D. DeZure0Emily E. Coates1Zonghui Hu2Galina V. Yamshchikov3Kathryn L. Zephir4Mary E. Enama5Sarah H. Plummer6Ingelise J. Gordon7Florence Kaltovich8Sarah Andrews9Adrian McDermott10Michelle C. Crank11Richard A Koup12Richard M. Schwartz13Robert T. Bailer14Xiangjie Sun15John R. Mascola16Terrence M. Tumpey17Barney S. Graham18Julie E. Ledgerwood19Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthInfluenza Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and PreventionVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthInfluenza Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and PreventionVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of HealthAvian influenza: A vaccine for a deadly emergent strain A vaccine candidate to treat a deadly subtype of avian influenza was shown to induce protective antibodies in initial clinical trials. As of March 2017, avian influenza strain A/H7N9 has killed 497 people since 2013, with 1349 confirmed cases. Julie Ledgerwood and her team from the United States’ National Institutes of Health in collaboration with colleagues at the Centers for Disease Control and Prevention tested their two-stage vaccine protocol in humans, showing it to be effective and safe. The vaccine consists of an initial injection of viral DNA, which ‘primes’ the immune system to the pathogen, followed by a follow-up injection of an inactivated purified viral protein, which further boosts the host’s production of protective antibodies. The study shows the viability of this vaccine regimen and suggests further investigation into its appropriateness for treating avian influenza in humans.https://doi.org/10.1038/s41541-017-0016-6 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Adam D. DeZure Emily E. Coates Zonghui Hu Galina V. Yamshchikov Kathryn L. Zephir Mary E. Enama Sarah H. Plummer Ingelise J. Gordon Florence Kaltovich Sarah Andrews Adrian McDermott Michelle C. Crank Richard A Koup Richard M. Schwartz Robert T. Bailer Xiangjie Sun John R. Mascola Terrence M. Tumpey Barney S. Graham Julie E. Ledgerwood |
spellingShingle |
Adam D. DeZure Emily E. Coates Zonghui Hu Galina V. Yamshchikov Kathryn L. Zephir Mary E. Enama Sarah H. Plummer Ingelise J. Gordon Florence Kaltovich Sarah Andrews Adrian McDermott Michelle C. Crank Richard A Koup Richard M. Schwartz Robert T. Bailer Xiangjie Sun John R. Mascola Terrence M. Tumpey Barney S. Graham Julie E. Ledgerwood An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial npj Vaccines |
author_facet |
Adam D. DeZure Emily E. Coates Zonghui Hu Galina V. Yamshchikov Kathryn L. Zephir Mary E. Enama Sarah H. Plummer Ingelise J. Gordon Florence Kaltovich Sarah Andrews Adrian McDermott Michelle C. Crank Richard A Koup Richard M. Schwartz Robert T. Bailer Xiangjie Sun John R. Mascola Terrence M. Tumpey Barney S. Graham Julie E. Ledgerwood |
author_sort |
Adam D. DeZure |
title |
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial |
title_short |
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial |
title_full |
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial |
title_fullStr |
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial |
title_full_unstemmed |
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial |
title_sort |
avian influenza h7 dna priming vaccine is safe and immunogenic in a randomized phase i clinical trial |
publisher |
Nature Publishing Group |
series |
npj Vaccines |
issn |
2059-0105 |
publishDate |
2017-06-01 |
description |
Avian influenza: A vaccine for a deadly emergent strain A vaccine candidate to treat a deadly subtype of avian influenza was shown to induce protective antibodies in initial clinical trials. As of March 2017, avian influenza strain A/H7N9 has killed 497 people since 2013, with 1349 confirmed cases. Julie Ledgerwood and her team from the United States’ National Institutes of Health in collaboration with colleagues at the Centers for Disease Control and Prevention tested their two-stage vaccine protocol in humans, showing it to be effective and safe. The vaccine consists of an initial injection of viral DNA, which ‘primes’ the immune system to the pathogen, followed by a follow-up injection of an inactivated purified viral protein, which further boosts the host’s production of protective antibodies. The study shows the viability of this vaccine regimen and suggests further investigation into its appropriateness for treating avian influenza in humans. |
url |
https://doi.org/10.1038/s41541-017-0016-6 |
work_keys_str_mv |
AT adamddezure anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT emilyecoates anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT zonghuihu anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT galinavyamshchikov anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT kathrynlzephir anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT maryeenama anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT sarahhplummer anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT ingelisejgordon anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT florencekaltovich anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT sarahandrews anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT adrianmcdermott anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT michelleccrank anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT richardakoup anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT richardmschwartz anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT roberttbailer anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT xiangjiesun anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT johnrmascola anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT terrencemtumpey anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT barneysgraham anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT julieeledgerwood anavianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT adamddezure avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT emilyecoates avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT zonghuihu avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT galinavyamshchikov avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT kathrynlzephir avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT maryeenama avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT sarahhplummer avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT ingelisejgordon avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT florencekaltovich avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT sarahandrews avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT adrianmcdermott avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT michelleccrank avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT richardakoup avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT richardmschwartz avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT roberttbailer avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT xiangjiesun avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT johnrmascola avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT terrencemtumpey avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT barneysgraham avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial AT julieeledgerwood avianinfluenzah7dnaprimingvaccineissafeandimmunogenicinarandomizedphaseiclinicaltrial |
_version_ |
1724397096332689408 |